ClinicalTrials.gg
Active, not recruitingNCT06335849Updated Mar 13, 2025

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years

A Phase 1 interventional study of LYB004 25µg and LYB004 50µg in Herpes Zoster, sponsored by Guangzhou Patronus Biotech Co., Ltd.. Active, not recruiting at 1 site in Australia. Open to participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Guangzhou Patronus Biotech Co., Ltd. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Herpes Zoster with a site in Australia — none open to participants now, 3 under way, 1 of them phase 3. Herpes Zoster · Australia.

Planned enrollment
12th of 16
48 · median 484
Started
2024
with 2 others
Phase 1
6 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
Guangzhou Patronus Biotech Co., Ltd.

Among the 17 studies in Herpes Zoster with a site in Australia, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 15th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 17 studies in Herpes Zoster with a site in Australia is open now. The open studies under Herpes Zoster, anywhere →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Herpes Zoster with a site in Australia as a file.
02

Study summary

This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years.

Read the detailed description

A randomized, observer-blinded, positive-controlled, dose escalation trial will be conducted to observe the safety and immunogenicity of LYB004 in adults 50 to 70 years of age. A total of 48 healthy subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:1) to receive LYB004 or SHINGRIX. Two dose levels of LYB004 will be provided, low dose 25 μg and high dose 50 μg. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60, respectively.

03

Conditions studied

  • Herpes Zoster

Keywords

  • Recombinant Zoster Vaccine
  • Glycoprotein E
  • Varicella-Zoster Virus
  • Herpes zoster
  • Shingles
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A male or female aged 50 to 70 years inclusive at screening.
  2. Written obtained from the subject before any assessment is performed.
  3. Subjects who the investigator believes that they can and will comply with the requirements of the protocol. (e.g., complete the diary cards, and complete follow-up visits).
  4. Subjects must have a (BMI) between ≥18.0 and ≤35.0 kg/m\^2 at screening.
  5. Female subjects who are not pregnant or lactating. Female subjects with and their partners should use highly effective, medically accepted double-barrier and will not have pregnancy and fertility plan until study completion.

    • Female subjects of childbearing potential are defined as sexually mature women: 1) have not undergone hysterectomy, bilateral salpingectomy, and bilateral oophorectomy; 2) have had natural menses at any time in the preceding 12 consecutive months (without an alternative medical cause).
    • Highly effective double-barrier contraception is defined as use of a condom AND one of the following: Birth control pills (The Pill), Depot or injectable birth control, Intrauterine device (IUD), Birth Control Patch (e.g., Ortho Evra), NuvaRing®, Implantable contraception (e.g., Implanon).
  6. Males participating in this study must agree to use highly effective, medically accepted double-barrier contraception (as described above) and refrain from donating sperm until study completion.

Exclusion criteria

Exclusion Criteria:

  1. Tympanic temperature > 37.5°C at screening.
  2. History of HZ.
  3. Previous vaccination against HZ or varicella. Planned administration of VZV or HZ vaccination during the study (including an or non-registered vaccine), except for the investigational vaccine.
  4. Received a within 28 days before vaccination or received other vaccines within 14 days before vaccination.
  5. Received any immunoglobulins or blood/plasma products within 3 months prior to vaccination.
  6. Individuals with the following diseases: 1)Any acute disease or acute attack of chronic diseases or using antipyretic, analgesic or anti-allergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days prior to enrolment; 2)Allergies to any component of the investigational vaccine; 3)Subject has any history of allergic conditions to other vaccines. 4)History of neurological disorders (convulsions, epilepsy, encephalopathy, etc.) or psychiatric disorders (bipolar disorder, schizophrenia, etc.) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study; 5)Asplenia, or functional asplenia; 6)Congenital or acquired immunodeficiency or disease; 7)Chronic administration (≥14 consecutive days) of (reference value for dose: ≥20 mg/day prednisone or equivalent) or other agents within the past 3 months, with the exception of inhaled or topical steroids, or short-term use (\<14 consecutive days) of oral corticosteroids; 8)Has severe cardiovascular diseases (cardiopulmonary disease, pulmonary edema), severe hepatic or renal diseases, and diabetes complications that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study; 9)History of thrombocytopenia or other coagulation disorders which may be for an IM; 10)Severe hypertension uncontrolled by medication with systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg; 11)Positive test for virus (HCV), surface antigen (HbsAg), (HIV) at screening; 12)Any skin condition and/or tattoo that may interfere with the evaluation of safety at the injection site.
  7. Clinically significant laboratory abnormalities determined by the investigator prior to vaccination.
  8. A positive urine drug test or alcohol breath test or a history of drug or alcohol abuse in the past 1 years.
  9. Recent participation in another clinical trial, with receipt of the investigational drug/vaccine within 30 days prior to screening. Current participation or those planning to participate in another clinical trial during the study.
  10. Other conditions that may impact the subject's safety or influence the assessment of vaccine response, as determined by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Treatment 1 (LYB004 25µg)

    Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.

    Biological: LYB004 25µg

  • Experimental
    Treatment 2 (LYB004 50µg)

    Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.

    Biological: LYB004 50µg

  • Active comparator
    Treatment 3 (SHINGRIX)

    Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.

    Biological: SHINGRIX

Interventions

  • BiologicalLYB004 25µg

    Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.

  • BiologicalLYB004 50µg

    Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.

  • BiologicalSHINGRIX

    Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.

06

What researchers measure

Primary outcomes

  1. Evaluate the reactogenicity of LYB004 vaccine

    The incidence and severity of any adverse events (AEs) within 30 minutes after each vaccination

    Time frame: Within 30 minutes after each vaccination

  2. Evaluate the safety and reactogenicity of LYB004 vaccine

    The incidence and severity of any solicited local and systemic AEs and unsolicited AEs within 0-7 days after each vaccination

    Time frame: Within 0-7 days after each vaccination

  3. Evaluate the safety of LYB004 vaccine

    The incidence and severity of any AEs within 30 days after each vaccination

    Time frame: Within 30 days after each vaccination

  4. Evaluate the safety and tolerability in laboratory tests of LYB004 vaccine

    The occurrence of clinically significant laboratory abnormalities 3 days, 14 days after each vaccination and 90 days after the first vaccination

    Time frame: 3 days, 14 days after each vaccination and 90 days after the first vaccination

  5. Evaluate the SAEs and AESIs of LYB004 vaccine

    The incidence of any serious adverse events (SAEs) and adverse events of special interest (AESIs) from the first vaccination up to 6 months after the second vaccination

    Time frame: From the first vaccination up to 6 months after the second vaccination

Secondary outcomes

  1. Observe the humoral immunity of LYB004 vaccine

    The geometric mean concentration (GMC in mIU/ml), geometric mean fold rise (GMFR), and serum seroconversion rate (%) of gE antibodies at 14 and 30 days after each vaccination; the geometric mean titer (GMT in 1:X), GMFR, and serum seroconversion rate (%) of VZV antibodies at 14 and 30 days after each vaccination

    Time frame: At 14 and 30 days after each vaccination

  2. Observe the cellular immunity of LYB004 vaccine

    The frequency and the cell mediated immunity (CMI) response rate (%) of gE-specific CD4\^2+ and CD8\^2+ T cells (expressing at least 2 different activation markers: IFN-γ, IL-2, TNF-α, and CD40L) per 10\^6 CD4 and CD8 T cells at 30 days after the second vaccination

    Time frame: At 30 days after the second vaccination

  3. Observe the persistence of humoral immunity of LYB004 vaccine

    The GMC in mIU/ml, GMFR, and serum seroconversion rate (%) of gE antibodies at 6 months after the second vaccination; the GMT in 1:X, GMFR, and serum seroconversion rate (%) of VZV antibodies at 6 months after the second vaccination

    Time frame: At 6 months after full vaccination

  4. Observe the persistence of cellular immunity of LYB004 vaccine

    The frequency and the CMI response rate (%) of gE-specific CD4\^2+ and CD8\^2+T cells per 10\^6 CD4 and CD8 T cells at 6 months after the second vaccination

    Time frame: At 6 months after full vaccination

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2025, 18 months after the start.

Of 21 phase 1 interventional studies under Herpes Zoster, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 28, 2024
StartActual
Mar 27, 2024
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06335849
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Collaborators
Yantai Patronus Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Mar 27, 2024
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Mar 13, 2025

Study contacts

Christina Chang, M.D
principal investigator · Nucleus Network Pty Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion